INTRODUCTION
MicroRNAs (miRNAs) are an extensive class of small noncoding RNA molecules, processed from much longer primary transcripts. miRNAs can repress the expression of many important target genes by binding to imperfect complementary sites within the 3 0 -untranslated regions (3 0 -UTRs) of mRNA. In recent years, some miRNAs have been shown to regulate gene expression by targeting coding region directly. 1 By regulating the expression of target genes, miRNAs are involved in a variety of biological processes including proliferation, cell differentiation and apoptosis. 2 The dysregulation of these processes is also a hallmarker of cancer. Mutations of miRNA or their functional interactions with oncogenes and tumor suppressor genes may be involved in tumorigenesis.
Abnormal expression of miRNAs has been documented in numerous solid tumors and hematological malignancies, such as breast cancer, 3 lung cancer, 4 liver cancer, 5, 6 glioblastoma, 7 colorectal cancer, 8 acute promyelocytic leukemia, 9 acute lymphoblastic leukemia, 10 and chronic lymphocytic leukemia. 11 By regulating tumor suppressor genes or oncogenes, miRNAs likely have an important role in the tumorigenesis and development.
MicroRNA-138 (miR-138) is highly conserved among vertebrates and is involved in the organogenesis of several organs. 12 Downregulation of miR-138 has been frequently observed in a variety of tumors, including thyroid cancer, 13 head and neck squamous cell carcinoma, oral squamous cell carcinoma and tongue squamous cell carcinoma. 14, 15 Mature miR-138 can be generated from two primary transcript, pri-miR-138-1 and pri-miR-138-2. The miR-138-1 gene is located on chromosome 3(3p21) and miR-138-2 is located on chromosome 16 (16q13). Significantly, several critical oncogenes including ZEB2, EZH2 and hTERT have been reported to be regulated by miR-138 in certain cell lines. 13, 16, 17 These findings suggest that miR-138 has pivotal roles in tumorigenesis and tumor progression by acting as a tumor suppressor. However, there has been little report on function of miR-138 in hematological malignancies.
In this study, we sought to examine the expression of miR-138 in several leukemia cell lines and bone marrow mononuclear cells from patients. We further investigated the mechanisms underlying dysregulated expression of miR-138. We found that miR-138 was downregulated in chronic myeloid leukemia (CML). Overexpression of miR-138 in CML cells led to the inhibition of clonogenic growth of K562, Ku812 and bone marrow mononuclear cells from CML patients. miR-138 was upregulated in CML in association with the therapeutic response to imatinib. We further identified BCR-ABL and CCND3 as the direct target genes of miR-138, and GATA1 as the transcription factor regulating miR-138 expression. These findings suggest the presence of a dysregulated molecular network involving BCR-ABL, GATA1, miR-138 and CCND3 in CML.
RESULTS

miR-138 is downregulated in CML cells
To determine whether miR-138 was dysreglated in leukemia cells, we measured the expression of miR-138 by quantitative reverse transcription-PCR (qRT-PCR) in a panel of human leukemic cell lines and primary bone marrow mononuclear cells from two healthy donors. We found that miR-138 was variably expressed in human leukemic cells (Figure 1a ), with the highest transcript level in Jurkat cells, a T-lymphoblastic cell line, and lowest expression levels in K562 cells, a CML cell line, indicating that miR-138 could be downregulated in CML. We further analyzed the expression of miR-138 in primary bone marrow mononuclear cells from 17 CML patients (Supplementary Table 1 , patients no. 1-17). We found that, compared with that of healthy donors, miR-138 expression was significantly downregulated in bone marrow mononuclear cells from CML patients (Figure 1b ; Po0.01). Furthermore, we examined the miR-138 expression levels in bone marrow mononuclear cells from five CML patients prior to and following imatinib treatment about 6 months (Supplementary Table 2 ). Our qRT-PCR assays demonstrated that miR-138 expression levels in bone marrow mononuclear cells decreased remarkably when CML cells were killed by imatinib in all five CML patients ( Figure 1c ). All these findings suggest that the expression of miR-138 was dysregulated in CML cells.
miR-138 overexpression inhibits the proliferation and clonogenic growth of CML cells We were interested in whether miR-138 exerted any effect on the clonogenic growth of CML cells. We first overexpressed miR-138 in K562 and Ku812 cells and examined the growth of K652 and Ku812 cells using the Cell Counting Kit-8 (CCK-8) kit. We observed that miR-138 overexpression was associated with a markedly reduced growth of K562 and Ku812 cells compared with those transfected with control RNA (Figures 2a and b) . And the proliferation of K562 and Ku812 cells was significantly promoted by miR-138 inhibitor (Figures 2a and b) . We further investigated whether miR-138 also inhibited the clonogenic growth of CML cells. Clonogenic assays revealed that K562 and Ku812 cells overexpressing miR-138 showed a marked reduction in both the size and number of colonies compared with cells mock transfected or transfected with control RNA (Figures 2c and d) . We further purified bone marrow mononuclear cells from three CML patients (patient no. [16] [17] [18] and then transfected these cells with miR-138 and were cultured for colony forming unit granulocyte-macrophage (CFU-GM). We found that the number of colonies from bone marrow mononuclear cells transfected with miR-138 was markedly lower than that of their counterparts, mock transfected or transfected with control RNA (Figures 2e-g ). Taken together, these findings show that miR-138 inhibits the proliferation and suppresses the clonogenic growth of CML cells. Figure 1 . miR-138 is downregulated in CML cell line K562 and primary bone marrow mononuclear cells from CML patients. (a) miR-138 expression was examined by qRT-PCR in several leukemia cell lines (HL-60, Kasumi-1, NB4, THP1, K562, Jurkat and Molt-4) and bone marrow mononuclear cells from two healthy donors (HD1 and HD2). The miR-138 expression level in HL-60 cells was set as standard, and miR-138 expression levels in other cells were determined by comparison to the standard. (b) miR-138 expression in bone marrow mononuclear cells from seven healthy donors (HD) and 17 CML patients (patients no. 1-17) was examined by qRT-PCR. The miR-138 expression from patient no. 6 was set as standard, and miR-138 expression levels in other samples were determined by comparison to the standard. (c) Total RNAs were extracted from bone marrow mononuclear cells from five CML patients before and after treatment with imatinib. miR-138 expression was analyzed by qRT-PCR. All data were obtained from three independent experiments in triplicate, and error bar indicated standard error. miR-138 overexpression induces G0/G1 arrest in K562 cells To understand whether the inhibition of clonogenic growth of CML cells by miR-138 was associated with cell cycle changes, we analyzed cell cycle distribution of K562 cells overexpressing miR-138. We found that miR-138 overexpression caused a 67.31% increase in the number of cells in the G0/G1 phase with a corresponding reduction in the number of cells in the S phase (Figure 3a) , suggesting that miR-138 overexpression causes a G0/G1 arrest. By miRNA target prediction with TargetScan, 18 a wellknown miRNA target prediction tool, we picked out four hypothetical target genes involved in cell cycle G0/G1 phase regulation. We then examined whether miR-138 modulated the expression of these hypothetical target genes involved in cell cycle regulation including CDK6, E2F2, E2F3 and CCND3 (Figure 3b ). We transfected K562 cells with miR-138 or control RNA and then examined the mRNA transcript levels of these four genes by qRT-PCR. We found that miR-138 overexpression caused no apparent change in the mRNA transcript levels of CDK6, E2F2 and E2F3 in K562 cells, while causing a marked inhibition of the mRNA transcript levels of CCND3, which encodes cyclin D3 (Figure 3c ). To test whether CCND3 was a direct target of miR-138, we inserted the wild-type or mutant 3 0 -UTR of human CCND3 containing putative miR-138 binding sites downstream of the coding sequence of the luciferase gene in the modified pGL3-control vector. Our luciferase assays revealed that co-transfection of miR-138 and the wild-type plasmid construct into HEK-293 cells caused a marked reduction in luciferase activity while miR-138 failed to suppress luciferase activities in HEK-293 cells expressing mutant CCND3 3 0 -UTR (Figure 3d ). Immunoblotting assays further showed that miR-138 overexpression caused an apparent decrease in the levels of cyclin D3 in K562 cells (Figure 3e ). Also we found that miR-138 could repress the expression of CCND3, but could not trigger Figure 2 . miR-138 inhibits the proliferation and clonogenic growth of K562, Ku812 and primary CML cells. miR-138, miR-138 inhibitor and corresponding control RNA were tranfected into K562 (a) and Ku812 (b) cells, viable cells were detected using the commercially available CCK-8 kit. *Po0.05 relative to control at 72 h by Student's t-tests, and # Po0.05 relative Inhibitor control at 72 h by Student's t-tests. (c) and (d) miR-138 and control RNA were transfected into K562 and Ku812 cells, and effects of miR-138 on colonies formation were determined (right panel) as described in Materials and methods. (e-g) Bone marrow mononuclear cells were isolated and purified from three CML patients (patient no. [16] [17] [18] and then transfected with miR-138. These cells were further cultured for CFU-GM. Effects of miR-138 on the clonogenic growth of these bone marrow mononuclear cells were investigated. All these data were obtained from three independent experiments in triplicate and error bar indicated s.e. A full colour version of this figure is available at the Oncogene journal online.
cell cycle arrest in Ku812 cells (data not shown). This may be because Ku812 cells is not sensitive to the repression of CCND3. Recently, CCND1 has been reported to be regulated by miR-138 in nasopharyngeal carcinoma cells, 19 but small interfering RNA (siRNA) against CCND3 could trigger G1 arrest in K562 cells whereas siRNA against CCND1 could not (data not shown). When this manuscript was in preparation, CCND3 was reported to be regulated by miR-138 in hepatocellular carcinoma cells. 20 Taken together, our findings suggest that CCND3 is a functional target of miR-138 in CML K562 cells. miR-138 is upregulated by imatinib and contributes to imatinibinduced apoptosis of CML cells To futher investigate the effect of miR-138 in CML cells, we examined the miR-138 expression levels in K562 and Ku812 cells prior to and following imatinib treatment. Our qRT-PCR assays demonstrated a marked increase in miR-138 levels following imatinib treatment and the increase was time-dependent in the two CML cell lines (Figures 4a and b) . miR-138 could induce G1 arrest in K562 cells itself, here we further found that miR-138 could enhance the cell cycle arrest effect triggered by imatinib BCR-ABL/GATA1/miR-138 circuitry in CML C Xu et al (Figure 4c ). When the expression of miR-138 was repressed by miR-138 inhibitor, imatinib-induced cell cycle arrest effect was attenuated (Supplementary Figure S2a) . We further found that miR-138 induced a marked increase in the percentage of apoptotic cells in the presence of imatinib (Figures 4d and e) , and imatinib-induced apoptosis was attenuated by the presence of miR-138 inhibitor (Supplementary Figure S2b) . In addition, miR-138 itself could induce a significant increase of apoptotic cells when K562 cells were transfected 96 h later (Supplementary Figure S3) . The data suggest that miR-138 could be upregulated by imatinib treatment, which, in turn, sensitizes K562 cells to imatinib-induced apoptosis.
miR-138 represses BCR-ABL and ABL expression by targeting the coding region of the ABL gene CML is characterized by the presence of the Philadelphia translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene encoding a constitutively active cytoplasmic tyrosine kinase that drives the growth of CML cells. 21 We have shown here that miR-138 could suppress the clonogenic growth of CML cells and is upregulated by imatinib. Therefore, we further test if miR-138 could modulate the expression of the BCR-ABL fusion gene in CML cells. Our qRT-PCR assays revealed that miR-138 overexpression markedly reduced the mRNA transcript levels of BCR-ABL, ABL1a and ABL1b while it had no effect on the expression of the BCR gene ( Figure 5a ). Our immunoblotting assays further showed that miR-138 overexpression caused an apparent reduction of BCR-ABL in K562 and Ku812 cells and ABL in HEK-293 cells (Figure 5b ). However, we failed to identify any putative miR-138 binding sites in the 3 0 -UTR of ABL1 using several conventional miRNA target prediction tools, such as TargetScan, PicTar and miRanda. 18, 22, 23 By using the RNAhybrid miRNA target prediction tool, 24 two putative miR-138 binding sites within the open reading frame of the ABL gene were found (Figure 5c ). Our luciferase assays further revealed that miR-138-mediated repression of BCR-ABL expression was independent of the 3 0 -UTR of ABL. In addition, we found that miR-138 targeted the second, not the first, putative miR-138 binding sequence of the ABL gene as luciferase activity was markedly repressed in cells co-transfected miR-138 with plasmid vectors containing the second, but not the first, putative miR-138-binding site (Figure 5d ), which was restored by the co-transfection miR-138 with plasmid vector carrying the mutated second putative binding site (Figure 5e ). This was confirmed by our co-transfection of miR-138 and the ABL expression vectors in K562 cells, which led to a marked repression of ABL as shown in our immunoblotting assays; by contrast, miR-138 failed to suppress ABL expression upon co-transfection of K562 cells with the mutated ABL expression vector in the coding region (Figure 5f right). We further detected the expression levels of miR-138 after co-transfection of miR-138 and the ABL expression vectors by qRT-PCR (Figure 5f left) . Together, these data show that miR-138 downregulates the expression of BCR-ABL and ABL by targeting the coding region of the ABL gene.
GATA1 associates with the regulatory region of pri-miR-138-2 and modulates the expression of miR-138 We further investigated whether miR-138 was generated from primiR-138-1 or pri-miR-138-2 in NB4 and K562 cells. Our RT-PCR assays revealed that pri-miR-138-2 was expressed in both NB4 and K562 cells whereas pri-miR-138-1 was expressed in neither (Figure 6a ). These data suggest that miR-138 was processed from primary miR-138-2 in K562 cells, just as reported by Obernosterer et al. 25 Consistently, we found that the expression of pri-miR-138-2 was remarkably induced by imatinib in K562 cells in a timedependent manner (Figure 6b) . Similar results were also found in another CML-derived BCR-ABL-positive Ku812 cell line (data not shown). Moreover, pri-miR-138-2 was upregulated when BCR-ABL was repressed by specific siRNA (Figure 6c) , suggesting that dysregulated expression of miR-138 in K562 cells is BCR-ABLdependent. Interestingly, when miR-138 mimics were transfected into K562 cells, pri-miR-138-2 expression was increased significantly (Figure 6c ), suggesting the presence of a negative regulatory loop between miR-138 and BCR-ABL. The above data suggest that mature miR-138 in K562 cells is derived from the transcription of pri-miR-138-2. We then used the TFSEARCH program to search for transcription factors that regulate miR-138 expression (http://www.cbrc.jp/research/db/TFSEARCH.html). 26 We found that there were nine putative GATA1-binding sites in the transcriptional regulatory region of pri-miR-138-2 (Figure 6d ), a 2 kb region upstream of the transcription start sites for pri-miR-138-2. 27 The regulatory role of GATA1 in modulating the expression of miR-138 and pri-miR-138-2 was supported by our qRT-PCR findings that knockdown of GATA1 by specific siRNA in K562 cells was associated with a marked repression of the expression of both pri-miR-138-2 and mature miR-138 (Figure 6e ), whereas overexpression of GATA1 upregulated the expression of pri-miR-138-2 and mature miR-138 in HEK-293 cells (Figure 6f ). Imatinib could induce miR-138 expression in CML cell lines (Figures 4a and b ), but this effect was attenuated, to some extent, by siRNA against GATA1 (Supplementary Figure S4a) . The data above suggest that GATA1 is a transcription factor regulating miR-138 expression in K562 cells. We next investigated whether GATA1 could directly bind to the regulatory region of miR-138. Our chromatin immunoprecipitation (ChIP) assays revealed that, in K562 cells treated with imatinib, GATA1 was found to be associated with regions encompassing fragment 2 and 3, but not fragment 1 and 4 ( Figure 6g and Supplementary Figure S4b) , indicating that, indeed, GATA1 interacts with the pri-miR-138-2 regulatory region in vivo.
Expression level and transcriptional activity of GATA1 were upregulated by imatinib in CML cells To understand the regulation of miR-138 by GATA1, we analyzed the expression levels of GATA1 and its cofactor FOG1. 28 Western blotting analysis revealed that imatinib increased the expression of GATA1 in K562 cells (Figure 6h) . Similarly, our qRT-PCR assays indicated that imatinib induced the mRNA expression levels of GATA1 and FOG1 (Figure 6i) . Furthermore, the mRNA expressions of several GATA1 target genes, including EKLF, EPOR, Gfi-1B, and p45, 29, 30 increased remarkably in K562 cells upon treatment with imatinib ( Figure 6j ). All these data suggest that imatinib increased both the expression level and transcriptional activity of GATA1 and also upregulated GATA1 target genes. DISCUSSION CML is characterized by the t(9;22) chromosomal translocation, which results in the formation of the BCR-ABL fusion gene. 31, 32 The encoded protein BCR-ABL is a constitutively active BCR-ABL tyrosine kinase, which deregulates downstream signaling pathways. Imatinib mesylate (Gleevec) (Novartis, Basel, Switzerland), the front line treatment for CML, 33 specifically inhibits the BCR-ABL tyrosine kinase activities, decreases proliferation, enhances differentiation and confers susceptibility to apoptosis.
Recently, several miRNAs, including miR-17-92 and miR-203, have been reported to be dysregulated in CML patients. 34, 35 Interestingly, the dysregulation of some miRNAs are dependent upon BCR-ABL tyrosine kinase activity. For example, BCR-ABL upregulates the expression of the miR-17-92 cluster of oncomirs, which facilitate tumor progression, and miR-130a/b can be significantly reduced on BCR-ABL knockdown. 34, 36 Though dysregulated expression of miR-138 has been documented in a variety of tumors, it has not been reported for CML. Here, we found that miR-138 was downregulated in K562 cells and bone BCR-ABL/GATA1/miR-138 circuitry in CML C Xu et al marrow mononuclear cells from CML patients (Figures 1a and b) . More importantly, the repression of miR-138 in CML is shown here to be BCR-ABL-dependent (Figure 6c ). miR-138 was expressed at low level in two other cell lines (that is, HL-60 and Kasumi-1) lacking BCR-ABL, suggesting that miR-138 downregulation may also occur through BCR-ABL-independent mechanisms. Our data further showed that imatinib upregulated the expression of primary and mature miR-138 in K562 cells (Figures 4a and 6b) . These findings suggest the presence of an intimate relation between miR-138 and BCR-ABL in CML cells, which could impact on the therapeutic response to imatinib.
Imatinib has been shown to induce apoptosis and erythroid differentiation in BCR-ABL-positive K562 cells. 37 We showed here that though miR-138 exerts no remarkable apoptotic effects after BCR-ABL/GATA1/miR-138 circuitry in CML C Xu et al transfection of 48 h, its overexpression in the presence of imatinib promotes imatinib-induced apoptosis of K562 and Ku812 cells (Figures 4d and e) . Given the possible presence of a complex mini-circuitry among miR-138, GATA1 and BCR-ABL in CML cells, this intriguing finding implies that low levels of miR-138 in CML cells could contribute to the poor therapeutic response to imatinib in some patients, but it also raises the prospect of the use of miR-138 mimics or other therapeutic molecules to enhance the levels of miR-138 in CML cells to enhance therapeutic response to imatinib. The answers to these questions await further studies. GATA1, an erythroid-specific transcription activator, has been shown to serve as a general switch factor for erythroid development. 38 Our results indicated that the expression of GATA1 and its cofactor FOG-1 increased modestly in K562 cells treated with imatinib (Figure 6i) . Moreover, multiple GATA1 target genes were remarkably upregulated in K562 cells treated with imatinib (Figure 6j ). Similar findings have been reported by Morceau et al., 39 who have found that BCR-ABL inactivation by Radicicol led to the upregulation of many erythroid genes, including GATA1 cofactor FOG1. These data suggest that imatinib enhances the transcriptional activity of GATA1 in CML cells, which is involved in erythoid differentiation induced by imatinib. However, the precise molecular mechanisms of BCR-ABL-dependent induction of GATA1 transcriptional activity remain to be clarified. In addition, multiple putative GATA1-binding sites are present in the transcriptional regulatory of primary miR-138-2, suggesting a regulatory role of GATA1 in miR-138 expression (Figure 6d ). Our ChIP assays showed that indeed GATA1 became associated with the regulatory region of primary miR-138-2 upon treatment with imatinib (Figure 6g) , and we further found that overexpression of GATA1 upregulated the levels of primary and mature miR-138 (Figure 6f ). These results suggest that imatinib upregulates miR-138 expression by promoting GATA1 transcriptional activity.
miRNAs regulate the expression of many important target genes by binding to imperfect complementary sites within the 3 0 -UTRs of mRNAs. For example, miR-203 has been shown to regulate BCR-ABL directly by binding to the 3 0 -UTR of ABL. 35 Here, miR-138 was shown to repress the expression of BCR-ABL and ABL (Figures 5a and b) , but we found no putative miR-138 binding sites in the 3 0 -UTR of ABL (Figure 5c ). Luciferase assays also revealed that miR-138 had no effect on the 3 0 -UTR of ABL (Figure 5d) . Recently, some miRNAs have been shown to regulate gene expression by targeting gene-coding region directly. 1 We demonstrated in this study that miR-138 inhibited the expression of BCR-ABL and ABL by targeting ABL-coding region (Figures 5d-f) . To our knowledge, this is the first report of miRNA-mediated fusion gene repression by targeting the fusion gene-coding region. By targeting BCR-ABL and CCND3, miR-138 inhibits the proliferation of CML cells and enhances the apoptotic effect of imatinib.
Taken together, our results show that miR-138 is downregulated in CML cells and BCR-ABL modulates miR-138 expression by inhibiting the expression and transcriptional activity of GATA1. Imatinib inhibits BCR-ABL tyrosine kinase activity and activates GATA1, which upregulate miR-138 transcription. Accordingly, high levels of miR-138 repress expression of both BCR-ABL and CCND3, and hence the clinical efficacy of imatinib. In conclusion, we have identified a novel BCR-ABL/GATA1/miR-138 regulatory circuitry whose dysfunction may contribute to the pathogenesis of CML (Figure 7 ). Targeting this circuitry in addition to the use of imatinib, may help to further improve therapeutic response to imatinib.
MATERIALS AND METHODS
Patient samples
Bone marrow mononuclear cells were obtained from diagnosed CML patients in chronic phase and from healthy donors with informed consent.
All CML patient bone marrow mononuclear cells were enriched by Ficoll gradient centrifugation. The study was performed with the approval of the Medical Ethical Committee of Chinese PLA General Hospital, Beijing, China. The demographic and clinical characteristics of patients with CML are shown in Supplementary Tables 1 and 2. Cell culture K562, Ku812, HL-60, Kasumi-1, THP1, Jurkat, Molt-4 and NB4 cells were grown in RPMI-1640, containing 10% fetal bovine serum and 100 mg/ml penicillin/streptomycin. HEK-293 cells were cultured in Dulbecco's modified Eagle's medium, containing 10% fetal bovine serum and 100mg/ml penicillin/streptomycin. Where appropriate, K562 cells were treated with 1 mmol/l imatinib for 24 or 48 h. Transfection miRNAs and siRNAs used in the study were synthesized by GenePharma (Shanghai, China). siRNAs and miRNAs transfection were performed using HiPerFect (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The sequences of siRNA or miRNA were seen in Supplementary  Table 3 . In brief, 8 Â 10 5 cells were plated in a six-well plate, for each well, 12 ml siRNA or miRNA (20 mM), and 24 ml HiPerFect was added into 400 ml serum-free RPMI-1640. The complexes were added to cells with 400 ml complete medium and incubated for 6 h, then the 1.6 ml complete medium was replenished, and the final concentration of miRNA or siRNA was 100 nM. Total RNA and protein were prepared 48 h after transfection and were used for qRT-PCR or western blot analysis. The transfection efficiency was detected by FACScalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using FAM-labeled control RNA. This reagent exhibits at least 90% transfection efficiency in K562 cells (Supplementary Figure S1 ).
Plasmid construction
Wild-type putative miR-138 binding sites of CCND3 (3 0 -UTR) and ABL (3 0 -UTR and coding region) were amplified by PCR from complementary DNA (cDNA) of K562 cells. Mutant miR-138 binding sequences were generated by the overlap-extension PCR method. 40 Both wild-type and mutant miR-138 binding sequences were inserted downstream of the firefly luciferase-coding region of a modified pGL3-control plasmid (Promega, Madison, WI, USA), as described before. 41 The coding sequence of ABL was amplified from cDNA of K562 cells and inserted into pcDNA3.0 modified with Flag tag. Mutant ABL-coding sequence was inserted into the same expression vector. DNA fragment containing primary miR-138 was amplified from HepG2 genomic DNA and cloned into expression vector pcDNA3.0 (Invitrogen, Carlsbad, CA, USA). 41 GATA1 expression vector was a generous gift from Professor Changyan Li at the Institute of Radiation Medicine, Beijing, China. Primer sequences were list in Supplementary Table 3. qRT-PCR Total cellular RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's protocol. qRT-PCR was used to confirm the expression levels of mRNAs and miRNAs. For mRNA detection, reverse transcription was performed according to the protocol of Improm-II Reverse Transcriptase System (Promega) and qPCR was performed using the SYBR premix Ex Taq (TaKaRa, Dalian, China) in Mx3000p (Stratagene, La Jolla, CA, USA) supplied with analytical software. The mRNA levels of genes were normalized against those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). miRNA quantification was done using the TaqMan miRNA detection kit (Applied Biosystems, Foster City, CA, USA) using 100 ng RNA in the Mx3000p cycler by the comparative DCt method using U6 expression for normalization. Corresponding reverse transcription and PCR primers for miR-138, and U6 were obtained from Applied Biosystems. All reactions were performed in triplicate and at least three times independently.
ChIP assays
We investigated whether GATA1 directly binds to the region of miR-138 by ChIP assays. K562 cells were treated with 1 mmol/l imatinib and after 24 h incubation, treated and untreated cells were harvested, and subjected to ChIP assay by using the EZ-ChIP kit (Millipore, Billerica, MA, USA) according to the manufacturer's protocol. Chromatin fragments were immunoprecipitated with GATA1 antibody (Abcam, Cambridge, MA, USA) or rabbit BCR-ABL/GATA1/miR-138 circuitry in CML C Xu et al normal IgG (Abcam), and were amplified by PCR using four pairs of primers located near the putative GATA1-binding sites. The primer sequences are provided in Supplementary Table 3. Western-blotting assays Protein extracts were prepared using a modified Radio Immunoprecipitation Assay (RIPA) buffer with 0.5% SDS in the presence of a cocktail of proteinase inhibitors cocktail (Roche Applied Science, Indianapolis, IN, USA). The immunoblotting assays were carried out as previously depicted, 6 and the antibodies against the following proteins were used for the procedure: CCND3 (MBL), ABL and b-actin (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), GATA1 (Abcam), Flag tag (SigmaAldrich, St Louis, MO, USA). Protein bands were visualized using SuperSignal West Pico chemoluminescent substrate (Pierce, Rockford, IL, USA).
Luciferase assays HEK-293 cells were transfected in 24-well plates using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The transfection mixtures contained 100 ng of firefly luciferase reporter plasmid, 400 ng of plasmids expressing miR-138 primary transcripts and 1 ml Lipofectamine 2000. pRL-TK (Promega) was also transfected as a normalization control. Cells were collected 48 h after transfection, and luciferase activity was measured using a dual-luciferase reporter assay system (Promega). All experiments were performed in triplicate and at least three times independently.
Cell cycle analysis K562 cells were transfected with miRNAs or siRNAs where indicated. After 48 h incubation, these cells were harvested, washed once in phosphatebuffered saline and then fixed in 70% ethanol overnight. The cells were stained with 50 mg/ml propidium iodide and 100 mg/ml DNase-free RNase A. Data were acquired on a FACScalibur flow cytometer (Becton Dickinson) using Cellquest software, and the ModFit program (Verity Software House Inc., Topsham, ME, USA) was used to analyze the cell cycle profiles.
Annexin V apoptosis assays
Annexin V apoptosis assays were performed using Annexin V-FITC kit (Biolegend, San Diego, CA, USA) according to manufacturer's protocol. The stained cells were immediately analyzed on a FACScalibur flow cytometer (Becton Dickinson). The data were expressed as the percentage of apoptotic cells.
Cell proliferation assay
Cell proliferation was determined using CCK-8 (Dojindo, Kumamoto, Japan). K562 cells (3000 per well) were transfected with miR-138 or control RNA in 96-well plates. At the point of 24, 48 and 72 h, 10 ml CCK-8 reagents were added to each well and further incubated at 37 1C for 2 h. The number of viable cells was assessed by measurement of absorbance at 450 nm using Multiskan (Thermo Scientific, Asheville, NC, USA).
CFU assay K562 cells were transfected with miR-138 and 500 transfected cells/well were seeded in a fresh six-well plate with methylcellulose medium (MethoCult H4230, STEMCELL Technologies, Vancouver, BC, Canada) 24 h after transfection. The colonies were counted 7 days later.
For CFU-GM assay, the bone marrow mononuclear cells were purified from two CML patients and then transfected with miR-138 and control RNA twice with HiPerFect transfection reagent as instructed by manufacturers (Qiagen). The transfect efficiency was more than 30% (Supplementary Figure S1) . Transfected bone marrow mononuclear cells were plated in methylcellulose medium with granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell factor (SCF) and interleukin-3 (IL3). The colonies were counted after 14 days. The scoring criteria for colonies required at least 50 cells per colony. BCR-ABL/GATA1/miR-138 circuitry in CML C Xu et al
